BioTime Inc. (BTX) Moves Higher on Volume Spike for March 15

Equities Staff  |

BioTime Inc. (BTX) traded on unusually high volume on Mar. 15, as the stock gained 11.61% to close at $1.73. On the day, BioTime Inc. saw 2.51 million shares trade hands on 4,485 trades. Considering that the stock averages only a daily volume of 905,440 shares a day over the last month, this represents a pretty significant bump in volume over the norm.

Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.

The stock has traded between $2.81 and $0.66 over the last 52-weeks, its 50-day SMA is now $1.18, and its 200-day SMA $1.87. BioTime Inc. has a P/B ratio of 1.56.

BioTime Inc is a clinical-stage biotechnology company. Its objective is the development and commercialization of novel therapies developed with the help of the company's core technology platforms. The core therapeutic technologies are based on pluripotent stem cells that can become any of the cell types in the human body. Pluripotent stem cells have potential applications in many areas of medicine, including several age-related degenerative diseases and conditions for which there presently are no cures. The product portfolio includes Renevia, a potential treatment for HIV-related facial lipoatrophy; AST-VAC1, a cancer immunotherapy; and OpRegen, a potential therapy derived from pluripotent stem cells to treat the dry form of age-related macular degeneration.

Headquartered in Alameda, CA, BioTime Inc. has 95 employees and is currently under the leadership of CEO .

For a complete fundamental analysis analysis of BioTime Inc., check out Equities.com’s Stock Valuation Analysis report for BTX.

Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start

To get more information on BioTime Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: BTX’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

World Economic Forum at Davos 2019 - Dr Oliver Krause Founder Untitled Inc Part 1

Matt Bird sits down with Dr Oliver Krause, Founder Untitled Inc, in part 1 of this 2 part interview at the World Economic Forum at Davos 2019